David Jeffrey Huss

Title: David Jeffrey Huss: Innovator in Cancer Therapeutics

Introduction

David Jeffrey Huss is a prominent inventor based in Seattle, WA (US). He has made significant contributions to the field of cancer therapeutics, particularly through his innovative patents related to human papilloma virus (HPV) and T cell receptors.

Latest Patents

David Huss holds 2 patents that focus on advanced binding molecules. His first patent involves HPV-specific binding molecules, which include T cell receptors (TCRs) and antibodies that specifically recognize human papilloma virus (HPV) 16, including its E6 and E7 proteins. This patent also encompasses engineered cells containing these binding molecules and methods of treatment involving their administration. His second patent pertains to T cell receptors and engineered cells expressing these receptors, which target peptide epitopes of cancer antigens, particularly those associated with HPV-infected cells. This innovation is crucial for developing adoptive cell therapies.

Career Highlights

Throughout his career, David has worked with notable companies in the biotechnology sector, including Juno Therapeutics GmbH and Editas Medicine, Inc. His work has significantly advanced the understanding and treatment of HPV-related cancers.

Collaborations

David has collaborated with esteemed colleagues such as Stephen Jacob Goldfless and Brian J Belmont, contributing to the collective knowledge and innovation in cancer research.

Conclusion

David Jeffrey Huss is a key figure in the development of innovative cancer therapies, particularly through his patents on HPV-specific binding molecules and T cell receptors. His work continues to impact the field of oncology and offers hope for improved treatment options.